Machine learning helps construct diagnostic models for IPF
Researchers in China used machine learning to create diagnostic and prognostic models to aid in identifying idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Category archive page for News.| Pulmonary Fibrosis News
Researchers in China used machine learning to create diagnostic and prognostic models to aid in identifying idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
IPF treatment candidate CS014 was safe and well tolerated in volunteers in a Phase 1 trial, and showed early promise for reversing scarring.| Pulmonary Fibrosis News
Taladegib has been granted orphan drug designation in the U.S. and the European Union as a treatment for idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.| Pulmonary Fibrosis News
A Texas researcher received a $219,000 NIH grant to study the potential of a treatment for radiation-induced pulmonary fibrosis.| Pulmonary Fibrosis News
In CORAL, 165 IPF patients were given one of three doses of nalbuphine ER to test its ability to reduce cough frequency after six weeks.| Pulmonary Fibrosis News
Nerandomilast slowed lung function decline in people with IPF and PPF after a year of treatment, according to data from two clinical trials.| Pulmonary Fibrosis News
